Generic Olinvyk Availability
Last updated on Apr 10, 2025.
Olinvyk is a brand name of oliceridine, approved by the FDA in the following formulation(s):
OLINVYK (oliceridine - solution;intravenous)
-
Manufacturer: TREVENA
Approval date: October 30, 2020
Strength(s): 1MG/ML (1MG/ML) (discontinued) [RLD], 2MG/2ML (1MG/ML) (discontinued) [RLD], 30MG/30ML (1MG/ML) (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Olinvyk. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Opioid receptor ligands and methods of using and making same
Patent 11,077,098
Issued: August 3, 2021
Inventor(s): Yamashita Dennis & Gotchev Dimitar & Pitis Philip & Chen Xiao-Tao & Liu Guodong & Yuan Catherine C. K.
Assignee(s): Trevena, Inc.This application describes compounds that can act as opioid receptor ligands, which compounds can be used in the treatment of, for example, pain and pain related disorders.
Patent expiration dates:
- March 23, 2032✓✓✓
- March 23, 2032
-
Opioid receptor ligands and methods of using and making same
Patent 11,931,350
Issued: March 19, 2024
Inventor(s): Yamashita; Dennis et al.
Assignee(s): TREVENA, INC. (Chesterbrook, PA)This application describes compounds that can act as opioid receptor ligands, which compounds can be used in the treatment of, for example, pain and pain related disorders.
Patent expiration dates:
- March 23, 2032✓✓
- March 23, 2032
-
Opioid receptor ligands and methods of using and making same
Patent 8,835,488
Issued: September 16, 2014
Inventor(s): Yamashita Dennis & Gotchev Dimitar & Pitis Philip & Chen Xiao-Tao & Liu Guodong & Yuan Catherine C. K.
Assignee(s): Trevena, Inc.This application describes compounds that can act as opioid receptor ligands, which compounds can be used in the treatment of, for example, pain and pain related disorders.
Patent expiration dates:
- March 23, 2032✓✓✓
- March 23, 2032
-
Opioid receptor ligands and methods of using and making same
Patent 9,309,234
Issued: April 12, 2016
Inventor(s): Yamashita Dennis & Gotchev Dimitar & Pitis Philip & Chen Xiao-Tao & Liu Guodong & Yuan Catherine C. K.
Assignee(s): Trevena, Inc.This application describes compounds that can act as opioid receptor ligands, which compounds can be used in the treatment of, for example, pain and pain related disorders.
Patent expiration dates:
- March 23, 2032✓✓✓
- March 23, 2032
-
Opioid receptor ligands and methods of using and making same
Patent 9,642,842
Issued: May 9, 2017
Inventor(s): Yamashita Dennis & Gotchev Dimitar & Pitis Philip & Chen Xiao-Tao & Liu Guodong & Yuan Catherine C. K.
Assignee(s): Trevana, Inc.This application describes compounds that can act as opioid receptor ligands, which compounds can be used in the treatment of, for example, pain and pain related disorders.
Patent expiration dates:
- March 23, 2032✓✓
- March 23, 2032
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- October 30, 2025 - NEW CHEMICAL ENTITY
More about Olinvyk (oliceridine)
- Olinvyk consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: Opioids (narcotic analgesics)
- En español
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
